Literature DB >> 10780581

Helicobacter pylori modulation of gastric acid.

J Calam1.   

Abstract

Helicobacter pylori plays major causative roles in peptic ulcer disease and gastric cancer. Elevated acid secretion in patients with duodenal ulcers (DUs) contributes to duodenal injury, and diminished acid secretion in patients with gastric cancer allows carcinogen-producing bacteria to colonize the stomach. Eradication of H. pylori normalizes acid secretion both in hyper-secreting DU patients and hypo-secreting relatives of gastric cancer patients. Therefore, we and others have asked how H. pylori causes these disparate changes in acid secretion. H. pylori gastritis more or less restricted to the gastric antrum in DU patients is associated with increased acid secretion. This is probably because gastritis increases release of the antral acid-stimulating hormone gastrin and diminished mucosal expression of the inhibitory peptide somatostatin. Bacterial products and inflammatory cytokines including TNFalpha may cause these changes in endocrine function. Gastritis involving the gastric corpus tends to diminish acid secretion, probably because bacterial products and cytokines including IL-1 inhibit parietal cells. Pharmacological inhibition of acid secretion increases corpus gastritis in H. pylori-infected subjects, so it is envisaged that gastric hypo-secretion of any cause might become self-perpetuating. H. pylori-associated mucosal atrophy will also contribute to acid hypo-secretion and is more likely in when the diet is high in salt or lacking in antioxidant vitamins. Data on gastric acid secretion in patients with esophagitis are limited but suggest that acid secretion is normal or slightly diminished. Nevertheless, H. pylori infection may be relevant to the management of esophagitis because: (i) H. pylori infection increases the pH-elevating effect of acid inhibiting drugs; (ii) proton pump inhibitors may increase the tendency of H. pylori to cause atrophic gastritis; and (iii) successful eradication of H. pylori is reported to increase the likelihood of esophagitis developing in patients who had DU disease. Points (ii) and (iii) remain controversial and more work is clearly required to elucidate the relationship between H. pylori, acid secretion, gastric mucosa atrophy and esophagitis.

Entities:  

Mesh:

Year:  1999        PMID: 10780581      PMCID: PMC2579021     

Source DB:  PubMed          Journal:  Yale J Biol Med        ISSN: 0044-0086


  21 in total

1.  The British Society of Gastroenterology diamond jubilee meeting. Brighton, 18-21 March 1997. Abstracts.

Authors: 
Journal:  Gut       Date:  1997       Impact factor: 23.059

2.  The effect of gastrin-releasing peptide on gastrin and somatostatin messenger RNAs in humans infected with Helicobacter pylori.

Authors:  A H Gibbons; S Legon; M M Walker; M Ghatei; J Calam
Journal:  Gastroenterology       Date:  1997-06       Impact factor: 22.682

3.  Gastric secretion, gastric antibody status and pernicious anaemia in carcinoma of the stomach.

Authors:  N D Finlayson; R H Girdwood; R R Samson; D J Shearman
Journal:  Digestion       Date:  1969       Impact factor: 3.216

4.  Effect of N alpha-methyl-histamine on acid secretion in isolated cultured rabbit parietal cells: implications for Helicobacter pylori associated gastritis and gastric physiology.

Authors:  I L Beales; J Calam
Journal:  Gut       Date:  1997-01       Impact factor: 23.059

5.  Effect of Helicobacter pylori products and recombinant cytokines on gastrin release from cultured canine G cells.

Authors:  I Beales; M J Blaser; S Srinivasan; J Calam; G I Pérez-Pérez; T Yamada; J Scheiman; L Post; J Del Valle
Journal:  Gastroenterology       Date:  1997-08       Impact factor: 22.682

6.  Functional impairment of rat enterochromaffin-like cells by interleukin 1 beta.

Authors:  C Prinz; N Neumayer; S Mahr; M Classen; W Schepp
Journal:  Gastroenterology       Date:  1997-02       Impact factor: 22.682

7.  Histamine secretion from rat enterochromaffinlike cells.

Authors:  C Prinz; M Kajimura; D R Scott; F Mercier; H F Helander; G Sachs
Journal:  Gastroenterology       Date:  1993-08       Impact factor: 22.682

8.  Gastric acid secretion, oesophageal acid reflux, and oesophagitis in patients with symptomatic gastro-oesophageal reflux.

Authors:  M Matikainen
Journal:  Scand J Gastroenterol       Date:  1981       Impact factor: 2.423

9.  Iatrogenic Campylobacter pylori infection is a cause of epidemic achlorhydria.

Authors:  D Y Graham; L C Alpert; J L Smith; H H Yoshimura
Journal:  Am J Gastroenterol       Date:  1988-09       Impact factor: 10.864

Review 10.  Helicobacter pylori and hormones.

Authors:  J Calam
Journal:  Yale J Biol Med       Date:  1996 Jan-Feb
View more
  15 in total

1.  Effect of Th1 cytokines on acid secretion in pharmacologically characterised mouse gastric glands.

Authors:  I T Padol; R H Hunt
Journal:  Gut       Date:  2004-08       Impact factor: 23.059

Review 2.  Helicobacter pylori infection and diabetes: is it a myth or fact?

Authors:  Cong He; Zhen Yang; Nong-Hua Lu
Journal:  World J Gastroenterol       Date:  2014-04-28       Impact factor: 5.742

3.  The effect of Helicobacter pylori on insulin resistance.

Authors:  Selim Aydemir; Taner Bayraktaroglu; Mehmet Sert; Coskun Sokmen; Hulusi Atmaca; Gorkem Mungan; Banu Dogan Gun; Ali Borazan; Yucel Ustundag
Journal:  Dig Dis Sci       Date:  2005-11       Impact factor: 3.199

4.  Effect of purified lipopolysaccharides from strains of Helicobacter pylori and Helicobacter felis on acid secretion in mouse gastric glands in vitro.

Authors:  I T Padol; A P Moran; R H Hunt
Journal:  Infect Immun       Date:  2001-06       Impact factor: 3.441

Review 5.  Pathogenesis of Helicobacter pylori infection.

Authors:  Johannes G Kusters; Arnoud H M van Vliet; Ernst J Kuipers
Journal:  Clin Microbiol Rev       Date:  2006-07       Impact factor: 26.132

Review 6.  Diabetes and gastric cancer: the potential links.

Authors:  Chin-Hsiao Tseng; Farn-Hsuan Tseng
Journal:  World J Gastroenterol       Date:  2014-02-21       Impact factor: 5.742

7.  Treatment of Helicobacter gastritis with IL-4 requires somatostatin.

Authors:  Yana Zavros; Sivaprakash Rathinavelu; John Y Kao; Andrea Todisco; John Del Valle; Joel V Weinstock; Malcolm J Low; Juanita L Merchant
Journal:  Proc Natl Acad Sci U S A       Date:  2003-10-10       Impact factor: 11.205

Review 8.  Treatment of acid-related diseases in the elderly with emphasis on the use of proton pump inhibitors.

Authors:  Bjarni Thjodleifsson
Journal:  Drugs Aging       Date:  2002       Impact factor: 3.923

Review 9.  Role of CCK/gastrin receptors in gastrointestinal/metabolic diseases and results of human studies using gastrin/CCK receptor agonists/antagonists in these diseases.

Authors:  Marc J Berna; Robert T Jensen
Journal:  Curr Top Med Chem       Date:  2007       Impact factor: 3.295

10.  Insulin resistance in children with Helicobacter pylori infection.

Authors:  S Ozdem; M Akcam; A Yilmaz; R Artan
Journal:  J Endocrinol Invest       Date:  2007-03       Impact factor: 4.256

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.